Sara Gilgore

3 weeks ago | bizjournals.com | Sara Gilgore

The D.C. Council just knocked down a barricade for the District’s health systems and medical practices, and those that want to enter the city. The D.C. Council just knocked down a barricade for the District’s health systems and medical practices — and those that want to enter the city.

1 month ago | bizjournals.com | Sara Gilgore

The National Institutes of Health has rescinded $1.4 million of a $2 million grant to Whitman-Walker Health System, putting construction of a biomedical research lab in Congress Heights in jeopardy. The health system — the entity within D.C.’s Whitman-Walker that encompasses a research institute, real estate division and foundation — had expected to start construction in the next month on the roughly $7.7 million project.

1 month ago | bizjournals.com | Sara Gilgore

Listen to this article 4 minThe 6-year-old company, which connects health care provider organizations with clinical workers, aims to double its number of hospital clients over the next 18 months. McLean’s ShiftMed LLC is taking steps to capture more business in the health care staffing space, as hospitals search for new ways to both drive revenue and trim expenses to mitigate expected cuts to their funding.

1 month ago | bizjournals.com | Sara Gilgore

The Falls Church-based nonprofit says the tech will allow clinical provides to spend more time on patient care. Inova Health System is bringing a Pennsylvania company’s artificial-intelligence technology into its exam rooms, a move it says will lighten the load on its medical providers, and give them more bandwidth to focus strictly on care.

1 month ago | bizjournals.com | Sara Gilgore

Gaithersburg’s Shuttle Pharmaceuticals Holdings Inc. (NASDAQ: SHPH) has brought in a new executive to spearhead the biotech’s business activity, freeing up its longtime leader, a cancer doctor and physician administrator, to focus on research and development. The company’s co-founder and chief executive, Dr. Anatoly Dritschilo, is now one of two co-CEOs, and will oversee the clinical trials and scientific work required to get its lead candidate for an aggressive brain cancer to patients.